AU2001227837A1 - Novel treatment for eye disease - Google Patents

Novel treatment for eye disease

Info

Publication number
AU2001227837A1
AU2001227837A1 AU2001227837A AU2783701A AU2001227837A1 AU 2001227837 A1 AU2001227837 A1 AU 2001227837A1 AU 2001227837 A AU2001227837 A AU 2001227837A AU 2783701 A AU2783701 A AU 2783701A AU 2001227837 A1 AU2001227837 A1 AU 2001227837A1
Authority
AU
Australia
Prior art keywords
eye disease
novel treatment
novel
treatment
eye
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001227837A
Inventor
James Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Light Sciences Corp
Original Assignee
Light Sciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Light Sciences Corp filed Critical Light Sciences Corp
Publication of AU2001227837A1 publication Critical patent/AU2001227837A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0076—PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6847—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a hormone or a hormone-releasing or -inhibiting factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Radiation-Therapy Devices (AREA)
AU2001227837A 2000-01-12 2001-01-12 Novel treatment for eye disease Abandoned AU2001227837A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17568900P 2000-01-12 2000-01-12
US60175689 2000-01-12
PCT/US2001/000922 WO2001051087A2 (en) 2000-01-12 2001-01-12 Novel treatment for eye disease

Publications (1)

Publication Number Publication Date
AU2001227837A1 true AU2001227837A1 (en) 2001-07-24

Family

ID=22641231

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001227837A Abandoned AU2001227837A1 (en) 2000-01-12 2001-01-12 Novel treatment for eye disease

Country Status (6)

Country Link
US (2) US20020049247A1 (en)
EP (1) EP1267935A2 (en)
JP (1) JP2003519670A (en)
AU (1) AU2001227837A1 (en)
CA (1) CA2395567A1 (en)
WO (1) WO2001051087A2 (en)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030176663A1 (en) * 1998-05-11 2003-09-18 Eidgenossische Technische Hochscule Specific binding molecules for scintigraphy
US6602274B1 (en) * 1999-01-15 2003-08-05 Light Sciences Corporation Targeted transcutaneous cancer therapy
US6454789B1 (en) 1999-01-15 2002-09-24 Light Science Corporation Patient portable device for photodynamic therapy
CA2356532A1 (en) 1999-01-15 2000-07-20 Light Sciences Corporation Noninvasive vascular therapy
US20030114434A1 (en) * 1999-08-31 2003-06-19 James Chen Extended duration light activated cancer therapy
US7897140B2 (en) 1999-12-23 2011-03-01 Health Research, Inc. Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
CA2398901C (en) 2000-02-10 2010-11-16 Massachusetts Eye And Ear Infirmary Methods and compositions for treating conditions of the eye
WO2001062800A1 (en) * 2000-02-24 2001-08-30 Eidgenössische Technische Hochschule Zürich Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis
CA2403612A1 (en) 2000-03-24 2001-10-11 Romulus Kimbro Brazzell Improved treatment of neovascularization
CA2421783A1 (en) * 2000-09-07 2002-03-14 Schering Aktiengesellschaft Receptor in the edb fibronectin domain
US7753943B2 (en) * 2001-02-06 2010-07-13 Qlt Inc. Reduced fluence rate PDT
US6875165B2 (en) * 2001-02-22 2005-04-05 Retinalabs, Inc. Method of radiation delivery to the eye
GEP20063755B (en) * 2001-11-09 2006-02-27 Eyetech Pharmaceuticals Use of VEGF Inhibiting Agents for Treating Ocular Neovascular Diseases
WO2003047633A2 (en) * 2001-12-04 2003-06-12 Nanospectra Biosciences, Inc. Treatment of angiogenesis disorders using targeted nanoparticles
DE60328496D1 (en) 2002-06-27 2009-09-03 Health Research Inc Fluorinierte chlorin und bacteriochlorin photosensitizer für fotodynamische therapie
WO2004004757A1 (en) * 2002-07-02 2004-01-15 The Regents Of The University Of California Treatment for eye disorder
AU2003299201A1 (en) 2002-10-03 2004-04-23 Light Sciences Corporation Excitation of photoreactive compounds in eye tissue
AU2003292838A1 (en) * 2002-12-27 2004-07-29 Kirin Beer Kabushiki Kaisha Therapeutic agent for wet age-related macular degeneration
EP1605847B1 (en) * 2003-03-07 2009-09-16 Board Of Regents, The University Of Texas System Antibody-targeted photodynamic therapy
CA2539288C (en) * 2003-09-15 2015-05-12 Shaker A. Mousa Thyroid hormone analogs and methods of use
US9198887B2 (en) 2003-09-15 2015-12-01 Nanopharmaceuticals Llc Thyroid hormone analogs and methods of use
US8071134B2 (en) * 2003-09-15 2011-12-06 Ordway Research Institute, Inc. Thyroid hormone analogs and methods of use
US8668926B1 (en) 2003-09-15 2014-03-11 Shaker A. Mousa Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
US7563222B2 (en) * 2004-02-12 2009-07-21 Neovista, Inc. Methods and apparatus for intraocular brachytherapy
ATE488269T1 (en) * 2004-02-12 2010-12-15 Neovista Inc DEVICE FOR INTRAOCULAR BRACHYTHERAPY
US7785591B2 (en) * 2004-10-14 2010-08-31 Morphosys Ag Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
US20060223750A1 (en) * 2005-04-01 2006-10-05 Allergan, Inc. Agents and methods for enhancing photodynamic therapy
US10130686B2 (en) 2005-09-15 2018-11-20 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating inflammatory disorders
US9498536B2 (en) 2005-09-15 2016-11-22 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating anti-inflammatory disorders
US9220788B2 (en) * 2009-06-17 2015-12-29 Nanopharmaceuticals Llc Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
US20100209382A1 (en) 2005-09-16 2010-08-19 Ordway Research Institute, Inc. Polyphenol Conjugates as RGD-Binding Compounds and Methods of Use
JP2009514540A (en) * 2005-11-09 2009-04-09 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト Identification and characterization of function-blocking anti-ED-B-fibronectin antibody (PRIVATE)
BRPI0618677A2 (en) 2005-11-15 2011-09-06 Neovista Inc methods and apparatus for intraocular brachytherapy
GB2435211B (en) 2006-01-25 2009-08-26 Alan Whitmore Drug delivery system
EP2120913B1 (en) * 2006-12-22 2015-01-21 NanoPharmaceuticals LLC Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
WO2008098300A1 (en) * 2007-02-14 2008-08-21 Opto Global Holdings Pty Ltd Method and system for control of therapeutic procedure
US8253725B2 (en) * 2007-12-28 2012-08-28 St. Jude Medical, Atrial Fibrillation Division, Inc. Method and system for generating surface models of geometric structures
US8353812B2 (en) 2008-06-04 2013-01-15 Neovista, Inc. Handheld radiation delivery system
WO2010075332A1 (en) * 2008-12-23 2010-07-01 Charitable Leadership Foundation Small molecule ligands of the integrin rgd recognition site and methods of use
US9180107B2 (en) * 2009-03-31 2015-11-10 Nanopharmaceuticals Llc Combination treatment of cancer with cetuximab and tetrac
US8948863B2 (en) 2009-10-09 2015-02-03 Board Of Regents, The University Of Texas System Photokinetic ocular drug delivery methods and apparatus
WO2011060033A1 (en) * 2009-11-10 2011-05-19 Immunolight, L.L.C. Up and down coversion systems for production of emitted light from various energy sources including radio frequency, microwave energy and magnetic induction sources for upconversion
US9622911B2 (en) 2010-09-30 2017-04-18 Cxl Ophthalmics, Llc Ophthalmic treatment device, system, and method of use
US8802240B2 (en) 2011-01-06 2014-08-12 Nanopharmaceuticals Llc Uses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensitivity and radiosensitivity in tumor or cancer cells
RU2467777C1 (en) * 2011-07-26 2012-11-27 Федеральное государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова Федерального агентства по высокотехнологичной медицинской помощи" Method of photodynamic therapy of intraocular neoplasms
EP2830637A4 (en) 2012-03-29 2016-03-16 Cxl Ophthalmics Llc Compositions and methods for treating or preventing diseases associated with oxidative stress
WO2013148896A1 (en) 2012-03-29 2013-10-03 Cxl Ophthalmics, Llc Ocular treatment solutions, delivery devices and delivery augmentation methods
GB2517707B (en) 2013-08-28 2020-09-02 Pci Biotech As A device for light-induced rupture of endocytic vesicles to effect the delivery of an antigen
AU2017214475B2 (en) 2016-02-04 2024-03-28 Ads Therapeutics Llc Antibody-drug synergism technology for treating diseases
CN109715551A (en) 2016-06-07 2019-05-03 纳米药业有限责任公司 With 3 integrin throstatics of α v β conjugation can not polymer pyrolysis
US10328043B1 (en) 2018-04-11 2019-06-25 Nanopharmaceuticals, Llc. Composition and method for dual targeting in treatment of neuroendocrine tumors
US11351137B2 (en) 2018-04-11 2022-06-07 Nanopharmaceuticals Llc Composition and method for dual targeting in treatment of neuroendocrine tumors
US10961204B1 (en) 2020-04-29 2021-03-30 Nanopharmaceuticals Llc Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumors
US11529153B2 (en) 2020-08-21 2022-12-20 University Of Washington Vaccine generation
WO2022040258A1 (en) 2020-08-21 2022-02-24 University Of Washington Disinfection method and apparatus
US11425905B2 (en) 2020-09-02 2022-08-30 University Of Washington Antimicrobial preventive netting
US11458220B2 (en) 2020-11-12 2022-10-04 Singletto Inc. Microbial disinfection for personal protection equipment
US11723888B2 (en) 2021-12-09 2023-08-15 Nanopharmaceuticals Llc Polymer conjugated thyrointegrin antagonists

Family Cites Families (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US18371A (en) * 1857-10-06 Improvement in sewing-machines
US44198A (en) * 1864-09-13 Improvement in vacuum apparatus for treating diseases
US30342A (en) * 1860-10-09 Improved packing-press
US114434A (en) * 1871-05-02 Improvement in dry-earth closets
US44197A (en) * 1864-09-13 Improvement in he at-radiator
US208249A (en) * 1878-09-24 Improvement in whip-rounding machines
US127224A (en) * 1872-05-28 Improvement in cotton-seed cleaners
US167033A (en) * 1875-08-24 Improvement in folding school-desks
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US4374925A (en) 1978-11-24 1983-02-22 Syva Company Macromolecular environment control in specific receptor assays
US4251762A (en) * 1979-03-16 1981-02-17 Moog Inc. Armature position detector
US4521762A (en) * 1981-08-27 1985-06-04 Gte Automatic Electric Laboratories, Incorporated Integratable D/A converter
US4649151A (en) * 1982-09-27 1987-03-10 Health Research, Inc. Drugs comprising porphyrins
US4577636A (en) * 1982-11-23 1986-03-25 The Beth Israel Hospital Association Method for diagnosis of atherosclerosis
US4753958A (en) * 1985-02-07 1988-06-28 University Of Cal Photochemotherapy of epithelial diseases with derivatives of hematoporphyrins
EP0220601B1 (en) * 1985-10-21 1991-12-11 Daiichi Seiyaku Co., Ltd. Pyranoindolizine derivatives and preparation process thereof
US5534506A (en) * 1986-01-02 1996-07-09 University Of Toledo Use of purpurins, chlorins and purpurin- and chlorin-containing compositions
US4861876A (en) * 1986-11-26 1989-08-29 Wayne State University Hematoporphyrin derivative and method of preparation and purification
US5494793A (en) * 1986-12-15 1996-02-27 British Technology Group Usa Inc. Monomeric phthalocyanine reagents
US5283255A (en) * 1987-01-20 1994-02-01 The University Of British Columbia Wavelength-specific cytotoxic agents
US5171749A (en) 1987-01-20 1992-12-15 University Of British Columbia Wavelength-specific cytotoxic agents
US4878891A (en) 1987-06-25 1989-11-07 Baylor Research Foundation Method for eradicating infectious biological contaminants in body tissues
US5503637A (en) 1987-06-26 1996-04-02 Light Sciences, Inc. Apparatus for producing and delivering high-intensity light to a subject
US4957481A (en) * 1987-10-01 1990-09-18 U.S. Bioscience Photodynamic therapeutic technique
US5919217A (en) 1987-12-08 1999-07-06 Medic-Light, Inc. Portable phototherapy unit
US4823244A (en) 1988-01-29 1989-04-18 Niagara Medical Innovations Inc. Light source assembly
US5026367A (en) 1988-03-18 1991-06-25 Cardiovascular Laser Systems, Inc. Laser angioplasty catheter and a method for use thereof
US5053006A (en) * 1988-04-19 1991-10-01 Watson Brant D Method for the permanent occlusion of arteries
US5002962A (en) * 1988-07-20 1991-03-26 Health Research, Inc. Photosensitizing agents
US4961920A (en) 1988-12-08 1990-10-09 Luminis Pty, Ltd. Phototherapeutic monovinyl and divinyl ether-linked dimers
US5028594A (en) * 1988-12-27 1991-07-02 Naxcor Use of photodynamic compositions for cytotoxic effects
US5041078A (en) * 1989-03-06 1991-08-20 Baylor Research Foundation, A Nonprofit Corporation Of The State Of Texas Photodynamic viral deactivation with sapphyrins
US5252720A (en) * 1989-03-06 1993-10-12 Board Of Regents, The University Of Texas System Metal complexes of water soluble texaphyrins
US4997639A (en) * 1989-11-27 1991-03-05 Nippon Petrochemicals Company, Limited Method for detecting cholesterol deposited in bodies of mammals
US5594136A (en) * 1989-12-21 1997-01-14 Pharmacyclics, Inc. Texaphyrin solid supports and devices
US5543514A (en) * 1989-12-21 1996-08-06 Board Of Regents, The University Of Texas System Water-soluble sapphyrins
US5238940A (en) 1990-03-22 1993-08-24 Quadra Logic Technologies Inc. Compositions for photodynamic therapy
US5484778C1 (en) * 1990-07-17 2001-05-08 Univ Cleveland Hospitals Phthalocynine photosensitizers for photodynamic therapy and methods for their use
US5827819A (en) 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
US5500009A (en) * 1990-11-15 1996-03-19 Amron, Ltd. Method of treating herpes
US5549660A (en) * 1990-11-15 1996-08-27 Amron, Ltd. Method of treating acne
US5869457A (en) 1991-03-11 1999-02-09 Rijksuniversiteit Te Groningen Modified proteins and their use for controlling viral infections
JP3154742B2 (en) * 1991-04-30 2001-04-09 日本石油化学株式会社 Remedy for mammalian atherosclerosis
US5263925A (en) 1991-07-22 1993-11-23 Gilmore Jr Thomas F Photopheresis blood treatment
US5222795A (en) 1991-12-26 1993-06-29 Light Sciences, Inc. Controlled light extraction from light guides and fibers
US5565552A (en) * 1992-01-21 1996-10-15 Pharmacyclics, Inc. Method of expanded porphyrin-oligonucleotide conjugate synthesis
US5330741A (en) * 1992-02-24 1994-07-19 The Regents Of The University Of California Long-wavelength water soluble chlorin photosensitizers useful for photodynamic therapy and diagnosis of tumors
ATE239506T1 (en) 1992-03-05 2003-05-15 Univ Texas USE OF IMMUNOCONJUGATES FOR THE DIAGNOSIS AND/OR THERAPY OF VASCULARIZED TUMORS
US5474765A (en) 1992-03-23 1995-12-12 Ut Sw Medical Ctr At Dallas Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells
US5807881A (en) * 1992-05-27 1998-09-15 Quadra Logic Technologies, Inc. Method for selectively reducing activated leukocyte cell population
US5976535A (en) * 1992-06-09 1999-11-02 Neorx Corporation Pretargeting protocols for the enhanced localization of cytotoxins to target sites and cytotoxic combinations useful therefore
CA2134239C (en) 1992-06-09 2004-11-23 Donald B. Axworthy Pretargeting methods and compounds
US6217869B1 (en) * 1992-06-09 2001-04-17 Neorx Corporation Pretargeting methods and compounds
IL102645A (en) * 1992-07-26 1998-02-22 Yeda Res & Dev Chlorophyll and bacteriochlorophyll derivatives, their preparation and pharmaceutical compositions comprising them
DE69316757T2 (en) 1992-07-31 1998-05-07 Behringwerke Ag PHOTOACTIVATIVE CHEMILUMINIZING MATRICES
US5298018A (en) * 1992-08-14 1994-03-29 Pdt Cardiovascular, Inc. Method for treating cardiovascular disease through adjunctive photodynamic therapy
JPH08505361A (en) * 1992-08-17 1996-06-11 クアドラ・ロジック・テクノロジーズ・インコーポレーテッド Method for destroying unwanted cells or tissues or inhibiting their growth
US5519008A (en) 1992-09-10 1996-05-21 Glycomed Incorporated Derivatives of triterpenoid acids as inhibitors of cell-adhesion molecules ELAM-1 (E-selectin) and LECAM-1 (L-selectin)
NZ255302A (en) * 1992-09-21 2001-04-27 Quadra Logic Tech Inc Method for impairing or destroying cells comprising the administration of a photoactive agent followed by irradiation with visible light
GB2272278B (en) 1992-10-23 1997-04-09 Cancer Res Campaign Tech Light source
ATE189966T1 (en) * 1992-11-20 2000-03-15 Univ British Columbia ACTIVATION OF PHOTOSENSITIVE AGENTS
US5368841A (en) * 1993-02-11 1994-11-29 The General Hospital Corporation Photodynamic therapy for the destruction of the synovium in the treatment of rheumatoid arthritis and the inflammatory arthritides
JP3565442B2 (en) * 1993-04-22 2004-09-15 新日本石油化学株式会社 Diagnostic and / or therapeutic agent for mammalian arthritis
US5482698A (en) 1993-04-22 1996-01-09 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin polymer conjugates
US5445608A (en) 1993-08-16 1995-08-29 James C. Chen Method and apparatus for providing light-activated therapy
JP3498960B2 (en) 1993-09-03 2004-02-23 デイド・ベーリング・マルブルク・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング Fluorescent oxygen channeling immunoassay
US5420768A (en) 1993-09-13 1995-05-30 Kennedy; John Portable led photocuring device
US5514669A (en) * 1993-09-29 1996-05-07 Medical College Of Ohio Use of photodynamic therapy to treat prostatic tissue
US5441531A (en) * 1993-10-18 1995-08-15 Dusa Pharmaceuticals Inc. Illuminator and methods for photodynamic therapy
US5913834A (en) 1993-11-04 1999-06-22 Francais; Caramia System for imparting sensory effects across a mother's abdomen to a fetus and monitoring effects on the fetus
US6015897A (en) * 1993-12-07 2000-01-18 Neorx Corporation Biotinamido-n-methylglycyl-seryl-o-succinamido-benzyl dota
US5840301A (en) * 1994-02-10 1998-11-24 Imclone Systems Incorporated Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors
IL108918A (en) 1994-03-10 1997-04-15 Medic Lightech Ltd Apparatus for efficient photodynamic treatment
AU6813694A (en) * 1994-03-14 1995-10-03 Massachusetts Eye & Ear Infirmary Use of green porphyrins in ocular diagnosis and therapy
US5798349A (en) * 1994-03-14 1998-08-25 The General Hospital Corporation Use of green porphyrins to treat neovasculature in the eye
US5556612A (en) * 1994-03-15 1996-09-17 The General Hospital Corporation Methods for phototherapeutic treatment of proliferative skin diseases
US5851225A (en) * 1994-03-18 1998-12-22 Spectra Science Corporation Photoemitting catheters and other structures suitable for use in photo-dynamic therapy and other applications
US5616140A (en) 1994-03-21 1997-04-01 Prescott; Marvin Method and apparatus for therapeutic laser treatment
DE69514262T2 (en) * 1994-03-23 2001-10-11 Yasuo Hashimoto Optical fiber catheter
US5456661A (en) 1994-03-31 1995-10-10 Pdt Cardiovascular Catheter with thermally stable balloon
US5498710A (en) * 1994-04-22 1996-03-12 Health Research, Inc. Alkyl ether analogues of benzoporphyrin derivatives
US5591847A (en) * 1994-05-23 1997-01-07 Health Research, Inc. Long wavelength absorbing photosensitizers related to purpurin-18, bacteriopurpurin-18 and related compounds with imide linkages
AU3374795A (en) * 1994-08-29 1996-03-22 Prizm Pharmaceuticals, Inc. Conjugates of vascular endothelial growth factor with targeted agents
US5877279A (en) * 1994-10-13 1999-03-02 Nanoframes, Llc Materials for the production of nanometer structures and use thereof
US5746494A (en) 1994-11-22 1998-05-05 Asahi Kogaku Kogyo Kabushiki Kaisha Illuminating apparatus of endoscope
DE4445065A1 (en) * 1994-12-07 1996-06-13 Diagnostikforschung Inst Methods for in-vivo diagnostics using NIR radiation
US5882328A (en) * 1995-01-13 1999-03-16 Qlt Phototherapeutics, Inc. Method to prevent transplant rejection
US6107325A (en) * 1995-01-17 2000-08-22 Qlt Phototherapeutics, Inc. Green porphyrins as immunomodulators
US5576013A (en) 1995-03-21 1996-11-19 Eastern Virginia Medical School Treating vascular and neoplastic tissues
FR2732094A1 (en) 1995-03-22 1996-09-27 Philips Eclairage LIGHT GENERATOR FOR OPTICAL FIBERS
US5735817A (en) 1995-05-19 1998-04-07 Shantha; T. R. Apparatus for transsphenoidal stimulation of the pituitary gland and adjoining brain structures
US5571152A (en) 1995-05-26 1996-11-05 Light Sciences Limited Partnership Microminiature illuminator for administering photodynamic therapy
IT1275571B (en) * 1995-07-19 1997-08-07 Consiglio Nazionale Ricerche FLUOROGENIC SUBSTRATES SUSCEPTIBLE FOR PHOTOACTIVATION AFTER ENZYMATIC TRANSFORMATION SUITABLE FOR DIAGNOSIS AND PHOTODYNAMIC CANCER THERAPY
JP2961074B2 (en) 1995-09-06 1999-10-12 明治製菓株式会社 Neovascular occlusive agents for photochemotherapy
AU7237896A (en) 1995-09-06 1997-03-27 Research Foundation Of The State University Of New York, The Two-photon upconverting dyes and applications
US5824080A (en) * 1995-09-28 1998-10-20 The General Hospital Corporation Photochemistry for the preparation of biologic grafts--allografts and xenografts
US5776175A (en) 1995-09-29 1998-07-07 Esc Medical Systems Ltd. Method and apparatus for treatment of cancer using pulsed electromagnetic radiation
US5800478A (en) * 1996-03-07 1998-09-01 Light Sciences Limited Partnership Flexible microcircuits for internal light therapy
US5835648A (en) 1996-03-07 1998-11-10 Miravant Systems, Inc. Surface illuminator for photodynamic therapy
US5770730A (en) * 1996-03-08 1998-06-23 Health Research, Inc. Synthesis of carbodimide analogs of chlorins and bacteriochlorins and their use for diagnosis and treatment of cancer
US5952366A (en) * 1996-03-08 1999-09-14 Health Research, Inc. Alkyl ether analogs of chlorins having an N-substituted imide ring
US5756541A (en) * 1996-03-11 1998-05-26 Qlt Phototherapeutics Inc Vision through photodynamic therapy of the eye
US5944748A (en) * 1996-07-25 1999-08-31 Light Medicine, Inc. Photodynamic therapy apparatus and methods
US5797868A (en) 1996-07-25 1998-08-25 Cordis Corporation Photodynamic therapy balloon catheter
US5814008A (en) * 1996-07-29 1998-09-29 Light Sciences Limited Partnership Method and device for applying hyperthermia to enhance drug perfusion and efficacy of subsequent light therapy
US5904147A (en) 1996-08-16 1999-05-18 University Of Massachusetts Intravascular catheter and method of controlling hemorrhage during minimally invasive surgery
US5715837A (en) * 1996-08-29 1998-02-10 Light Sciences Limited Partnership Transcutaneous electromagnetic energy transfer
US5849027A (en) * 1996-09-04 1998-12-15 Mbg Technologies, Inc. Photodynamic therapy method and apparatus
US5913884A (en) * 1996-09-19 1999-06-22 The General Hospital Corporation Inhibition of fibrosis by photodynamic therapy
US5702432A (en) 1996-10-03 1997-12-30 Light Sciences Limited Partnership Intracorporeal light treatment of blood
WO1998015273A1 (en) * 1996-10-10 1998-04-16 The General Hospital Corporation Photodynamic therapy for the treatment of osteoarthritis
GB9708265D0 (en) * 1997-04-24 1997-06-18 Nycomed Imaging As Contrast agents
US5832931A (en) * 1996-10-30 1998-11-10 Photogen, Inc. Method for improved selectivity in photo-activation and detection of molecular diagnostic agents
US5829448A (en) * 1996-10-30 1998-11-03 Photogen, Inc. Method for improved selectivity in photo-activation of molecular agents
US5741316A (en) * 1996-12-02 1998-04-21 Light Sciences Limited Partnership Electromagnetic coil configurations for power transmission through tissue
US6080160A (en) * 1996-12-04 2000-06-27 Light Sciences Limited Partnership Use of shape memory alloy for internally fixing light emitting device at treatment site
US6270749B1 (en) * 1996-12-11 2001-08-07 Pharmacyclics, Inc. Use of Texaphyrin in ocular diagnosis and therapy
US5876427A (en) * 1997-01-29 1999-03-02 Light Sciences Limited Partnership Compact flexible circuit configuration
US5782896A (en) * 1997-01-29 1998-07-21 Light Sciences Limited Partnership Use of a shape memory alloy to modify the disposition of a device within an implantable medical probe
US5746495A (en) 1997-02-05 1998-05-05 Klamm; Thomas L. Portable work light with optical fiber adapter
US5817048A (en) 1997-03-20 1998-10-06 Brown University Research Foundation Ultrasonic alternative to laser-based photodynamic therapy
US5827186A (en) 1997-04-11 1998-10-27 Light Sciences Limited Partnership Method and PDT probe for minimizing CT and MRI image artifacts
US5957960A (en) * 1997-05-05 1999-09-28 Light Sciences Limited Partnership Internal two photon excitation device for delivery of PDT to diffuse abnormal cells
CA2284879C (en) * 1997-05-07 2005-10-25 Qlt Phototherapeutics, Inc. Ethylene glycol esters of monohydrobenzoporphyrin derivatives as photoactive agents
US5921244A (en) * 1997-06-11 1999-07-13 Light Sciences Limited Partnership Internal magnetic device to enhance drug therapy
US6058937A (en) * 1997-07-18 2000-05-09 Miravant Systems, Inc. Photodynamic Therapy of highly vascularized tissue
CA2298526A1 (en) * 1997-07-28 1999-02-04 Dermatolazer Technologies Ltd Phototherapy based method for treating pathogens and composition for effecting same
US6048359A (en) * 1997-08-25 2000-04-11 Advanced Photodynamic Technologies, Inc. Spatial orientation and light sources and method of using same for medical diagnosis and photodynamic therapy
US5865840A (en) * 1997-10-22 1999-02-02 Light Sciences Limited Partnership Enhancement of light activation effect by immune augmentation
US6123923A (en) * 1997-12-18 2000-09-26 Imarx Pharmaceutical Corp. Optoacoustic contrast agents and methods for their use
US5945762A (en) * 1998-02-10 1999-08-31 Light Sciences Limited Partnership Movable magnet transmitter for inducing electrical current in an implanted coil
US20030030342A1 (en) * 1998-02-10 2003-02-13 Chen James C. Contactless energy transfer apparatus
US6416531B2 (en) * 1998-06-24 2002-07-09 Light Sciences Corporation Application of light at plural treatment sites within a tumor to increase the efficacy of light therapy
US6096066A (en) * 1998-09-11 2000-08-01 Light Sciences Limited Partnership Conformal patch for administering light therapy to subcutaneous tumors
US6117862A (en) * 1998-10-09 2000-09-12 Qlt, Inc. Model and method for angiogenesis inhibition
US6344050B1 (en) * 1998-12-21 2002-02-05 Light Sciences Corporation Use of pegylated photosensitizer conjugated with an antibody for treating abnormal tissue
ATE234114T1 (en) * 1999-01-15 2003-03-15 Light Sciences Corp THERAPEUTIC COMPOSITIONS FOR BONE METABOLIC DISORDERS OR BONE METASTASIS CONTAINING A PHOTOSENSITIZER AND A BISPHOSPHONATE
US6602274B1 (en) * 1999-01-15 2003-08-05 Light Sciences Corporation Targeted transcutaneous cancer therapy
US6162242A (en) * 1999-01-21 2000-12-19 Peyman; Gholam A. Selective photodynamic treatment
US6273904B1 (en) * 1999-03-02 2001-08-14 Light Sciences Corporation Polymer battery for internal light device
US6210425B1 (en) * 1999-07-08 2001-04-03 Light Sciences Corporation Combined imaging and PDT delivery system
US6238426B1 (en) * 1999-07-19 2001-05-29 Light Sciences Corporation Real-time monitoring of photodynamic therapy over an extended time
US20030114434A1 (en) * 1999-08-31 2003-06-19 James Chen Extended duration light activated cancer therapy
US6624187B1 (en) * 2000-06-12 2003-09-23 Health Research, Inc. Long wave length absorbing bacteriochlorin alkyl ether analogs
US20020127224A1 (en) * 2001-03-02 2002-09-12 James Chen Use of photoluminescent nanoparticles for photodynamic therapy
JP3463673B2 (en) * 2001-04-11 2003-11-05 日産自動車株式会社 Map data distribution device and map data distribution method
EP1467760A2 (en) * 2002-01-23 2004-10-20 Light Sciences Corporation Systems and methods for photodynamic therapy
DE60328496D1 (en) * 2002-06-27 2009-09-03 Health Research Inc Fluorinierte chlorin und bacteriochlorin photosensitizer für fotodynamische therapie
EP1606291A2 (en) * 2002-07-02 2005-12-21 Health Research, Inc. Efficient synthesis of pyropheophorbide a and its dervatives

Also Published As

Publication number Publication date
EP1267935A2 (en) 2003-01-02
US20060088530A1 (en) 2006-04-27
WO2001051087A2 (en) 2001-07-19
WO2001051087A3 (en) 2002-05-10
JP2003519670A (en) 2003-06-24
US7320786B2 (en) 2008-01-22
US20020049247A1 (en) 2002-04-25
CA2395567A1 (en) 2001-07-19

Similar Documents

Publication Publication Date Title
AU2001227837A1 (en) Novel treatment for eye disease
AU1948901A (en) Illuminating device for treating eye disease
AU2002223827A1 (en) Well treatment
AU2002305578A1 (en) Applanation tonometer
AUPQ514600A0 (en) Brain injury treatment
AU2001284646A1 (en) Quinuclidine-substituted heteroaryl moieties for treatment of disease
AU2001282875A1 (en) Quinuclidine-substituted heteroaryl moieties for treatment of disease
AU2001260513A1 (en) Microcapsule well treatment
AU2002348076A1 (en) Dual action ophthalmic implant extractor
AU2001233299A1 (en) Methods for treating alzheimer's disease
AU2001261262A1 (en) Glaucoma treatment device
AU2001269799A1 (en) Methods for treating various eye disorders
AU2001259702A1 (en) Tissue regrafting
AU2002317759A1 (en) Ophthalmoscope
AU2000265525A1 (en) Medicament for treating intestinal diseases
AU2001237939A1 (en) Methods for treating glaucoma
AU2002352363A1 (en) Eye speculum
AU2002236781A1 (en) Treatment for snoring
AU2371201A (en) Endoscope
AU2001290325A1 (en) Eye drops
GB0029524D0 (en) Disease treatment
AU2001228863A1 (en) Remedies for ophthalmic diseases
AUPR069500A0 (en) Tissue modification
AU2001271026A1 (en) Remedies for bone diseases
AU2001229209A1 (en) Hydrokeratome for refractive surgery